ÌÇÐÄÆƽâ°æ

Revenue share from major pharmaceutical companies' top 3 products in 2024

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

June 2025

Region

Worldwide

Survey time period

2024

Supplementary notes

Values show percentages of the companies' total prescription drug sales. All values were calculated based on provided sales figures.

Citation formats

Pharmaceutical companies — revenue from top 3 products 2024

Published by A. Minhas, Jun 26, 2025

In 2024, pharmaceutical company Novo Nordisk's top three products generated around ** percent of its total pharmaceutical revenues. In dollars, the Danish company's top three products generated around ** billion out of ** billion U.S. dollars in total. The numbers are even more astonishing, knowing that all three top products (Ozempic, Wegovy, Rybelsus) are, in fact, one and the same active ingredient — semaglutide.

This statistic shows the revenue generated by select pharmaceutical companies' top three products as a share of their total pharmaceutical revenues. A lower dependency on a few major products may be of advantage for a company, especially with regard to sales losses due to potential patent expiration.

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Novartis "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Novartis

Company positioning & scale

5

Financial scale & structure

6

Portfolio, segments & geography

5

Competitive landscape

5

R&D, pipeline & innovation

5

Outlook & risk

3

Further Content: You might find this interesting as well

Topics

AstraZenecaGlobal pharmaceutical industryPharmaceutical industry in the U.S.NovartisMerck & Co.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.